SEC Filing Summary: India Globalization Capital, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by India Globalization Capital, Inc. (not IGC Pharma, Inc.) on November 13, 2009, reporting an event that occurred on November 11, 2009. The Company is incorporated in Maryland and maintains its principal executive offices in Bethesda, Maryland.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Events
- Regulatory Warning: On November 11, 2009, the Company received a warning letter from NYSE Amex LLC staff.
- Violation Details: The warning concerned the issuance of common stock on September 18, 2009, prior to obtaining approval for listing on NYSE Amex.
- Compliance Status: The Company was found to be in non-compliance with Section 301 of the NYSE Amex Company Guide, which prohibits issuing additional securities before listing approval.
- Corrective Action: The listing application for the shares was submitted to NYSE Amex on November 12, 2009.
Outlook, Risks, and Management Commentary
Management indicated that the warning letter constitutes notice of failure to comply with a continued listing standard. However, the NYSE Amex staff stated they would not immediately apply the continued listing evaluation and follow-up procedures specified in Section 1009 of the Company Guide. The Company is actively working with the Exchange to ensure the shares are properly listed. A press release disclosing this event was issued on November 13, 2009.
Investor Verification Checklist
- Verify the current listing status of the shares issued on September 18, 2009, on NYSE Amex.
- Confirm whether the Company has received formal approval for the listing application submitted on November 12, 2009.
- Monitor for any future enforcement actions or delisting proceedings if the shares are not approved promptly.
- Review the attached press release (Exhibit 99.1) for additional details on the Company's response strategy.